The current P/E ratio for Supernus Pharmaceuticals stock as of Apr 26, 2024 is 1503.5. This is calculated based on the TTM EPS of $0.02 and the stock price of $30.07 per share. The current PE ratio is about the same compared to the last 4 quarters average.
The average historical PE ratio of Supernus Pharmaceuticals for the last ten years is 71.5. The current price-to-earnings ratio of 1503.5 is in line with the historical average. Analyzing the last ten years, SUPN's PE ratio reached its highest point in the Dec 2023 quarter at 1,447, when the price was $28.94 and the EPS was $0.02. The lowest point was recorded in the Mar 2020 quarter, when it reached 8.14 with a price of $17.99 and an EPS of $2.21.
Maximum annual increase: 4,483.47% in 2023
Maximum annual decrease: -70.39% in 2016
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 1,447 | 4,483.47% |
| 2022 | 31.57 | 9.35% |
| 2021 | 28.87 | 176.53% |
| 2020 | 10.44 | -4.92% |
| 2019 | 10.98 | -29.62% |
| 2018 | 15.6 | -55.77% |
| 2017 | 35.27 | 157.07% |
| 2016 | 13.72 | -70.39% |
| 2015 | 46.34 | N/A |
| 2014 | N/A | N/A |
The current PE ratio of SUPN is above its 3, 5 and 10-year averages.
SUPN's PE ratio is above its peer stocks LLY and JNJ.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.53 | $352.02B |
| UTHR UNITED THERAPEUTICS Corp | 11.11 | $11B |
| ABT Abbott Laboratories | 32.78 | $186.58B |
| LLY ELI LILLY & Co | 126.03 | $696.96B |
| SUPN Supernus Pharmaceuticals Inc | 1,503.5 | $1.65B |
| BMY Bristol Myers Squibb Co | N/A | $90.92B |
The price to earnings ratio for SUPN stock as of Apr 26, 2024, stands at 1,503.5.
Over the last 3 years, the average PE ratio for SUPN stock is 161.16.
Over the last 5 years, the average PE ratio for SUPN stock is 98.1.
Within the last ten years, the current price to earnings ratio is at its peak with a value of 1,503.5.
The current PE ratio of SUPN is 2,003% higher than the 10-year historical average.
SUPN's PE ratio is high because its earnings per share (EPS) is low relative to its stock price.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Apr 26, 2024), Supernus Pharmaceuticals's share price is $30.07. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $0.02. Therefore, Supernus Pharmaceuticals's price to earnings ratio for today is 1,503.5. PE RATIO(1,503.5) = STOCK PRICE($30.07) / TTM EPS($0.02)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.